PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Ocriplasmin (Jetrea) (125 mcg Intravitreal Injection): For the Treatment of Symptomatic Vitreomacular Adhesion [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2014 Jan.

5CONCLUSIONS

Two multi-centre, randomized, parallel group, double-masked, placebo-controlled studies comparing a single 125 mcg intravitreal injection of ocriplasmin with a placebo injection for the treatment of VMA were reviewed. Overall, treatment with ocriplasmin was superior to placebo for the resolution of VMA and total PVD. Although there was a greater overall incidence of AEs for patients treated with ocriplasmin compared with placebo, many events were transient and were possibly related to the procedure instead of the drug itself. There is uncertainty regarding the efficacy of ocriplasmin for the treatment of FTMHs, avoidance of vitrectomy, and improvement in BCVA. Moreover, no data were available on whether ocriplasmin prevents VMA-related vision loss or blindness, which are key outcomes according to patient groups.

Copyright © CADTH 2014.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Cover of Ocriplasmin (Jetrea) (125 mcg Intravitreal Injection)
Ocriplasmin (Jetrea) (125 mcg Intravitreal Injection): For the Treatment of Symptomatic Vitreomacular Adhesion [Internet].

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...